Mitoxantrone (Synonyms: Mitozantrone; NSC 301739)

Name: Mitoxantrone
Brand: MedChemExpress
SKU: HY-13502
Rating: 5.0 (29 reviews)

Cat. No.: HY-13502 Purity: 98.70%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity. Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively.

For research use only. We do not sell to patients.

Mitoxantrone Chemical Structure

CAS No. : 65271-80-9

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 29 publication(s) in Google Scholar

Other Forms of Mitoxantrone:

29 Publications Citing Use of MCE Mitoxantrone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

View All PKC Isoform Specific Products:

View All Isoforms

PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity^[1]^[2]^[3]^[4]. Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively^[5].

IC₅₀ & Target^[1]^[2]

PKC

8.5 μM (IC₅₀)

Topoisomerase II

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	7.8 nM Compound: Mitoxantrone	Antiproliferative activity against human 2008 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay Antiproliferative activity against human 2008 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	[PMID: 31465686]
A2780	IC₅₀	0.00055 μM Compound: Mitoxantrone	Concentration required to inhibit A2780-cell growth by 50% Concentration required to inhibit A2780-cell growth by 50%	[PMID: 9703471]
A2780	IC₅₀	0.00055 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs	[PMID: 9371240]
A-375	IC₅₀	111.5 nM Compound: Mitoxantrone	Cytotoxicity against human A375 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay Cytotoxicity against human A375 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	[PMID: 30925340]
A549	IC₅₀	0.036 nM Compound: Mitoxantrone	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 30485090]
A549	IC₅₀	15.7 μg/mL Compound: Mitoxantrone	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 26599534]
A549	IC₅₀	25.3 μg/mL Compound: Mito	Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay	10.1007/s00044-012-0325-2
A549	IC₅₀	3 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.	[PMID: 10956214]
A549	IC₅₀	7.25 μM Compound: Table S1, R142C2	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30684866]
A549	IC₅₀	7.8 μM Compound: Mitoxantrone	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 21507644]
A549	IC₅₀	7.8 μM Compound: Mitoxantrone	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21458279]
A549	IC₅₀	7.83 μM Compound: MX	Cytotoxicity against human A549 cells after 72 hrs Cytotoxicity against human A549 cells after 72 hrs	[PMID: 21354791]
A549	IC₅₀	8 μM Compound: Mitoxantrone	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 19615900]
A549	GI₅₀	8.3 μM Compound: Mitoxantrone	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 20153184]
Bel-7402	IC₅₀	116.6 nM Compound: Mitoxantrone	Cytotoxicity against human Bel7402 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay Cytotoxicity against human Bel7402 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	[PMID: 30925340]
C6	IC₅₀	10.9 μg/mL Compound: Mito	Cytotoxicity against Rattus norvegicus (rat) C6 cells after 24 hr by MTT assay Cytotoxicity against Rattus norvegicus (rat) C6 cells after 24 hr by MTT assay	10.1007/s00044-012-0325-2
C6	IC₅₀	11 μg/mL Compound: Mitoxantrone	Cytotoxicity against rat C6 cells after 24 hrs by MTT assay Cytotoxicity against rat C6 cells after 24 hrs by MTT assay	[PMID: 26599534]
Caco-2	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against NAE-knockdown human Caco2 cells after 72 hrs by MTT assay Cytotoxicity against NAE-knockdown human Caco2 cells after 72 hrs by MTT assay	[PMID: 29232579]
Caco-2	IC₅₀	1.4 μM Compound: 1	Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 29232579]
Cancer cell lines	IC₅₀	0.75 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human H460M cancer cell line was determined after 144 hr Cytotoxicity against human H460M cancer cell line was determined after 144 hr	[PMID: 15456268]
Cancer cell lines	IC₅₀	0.85 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human H460M cancer cell line was determined after 1 hr Cytotoxicity against human H460M cancer cell line was determined after 1 hr	[PMID: 15456268]
Cancer cell lines	IC₅₀	6.8 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human MKN45 cancer cell line was determined after 1 hr Cytotoxicity against human MKN45 cancer cell line was determined after 1 hr	[PMID: 15456268]
Cancer cell lines	IC₅₀	75 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human PC3 cancer cell line was determined after 1 hr Cytotoxicity against human PC3 cancer cell line was determined after 1 hr	[PMID: 15456268]
CCD 19Lu	IC₅₀	> 160 nM Compound: Mitoxantrone	Cytotoxicity in human CCD-19Lu cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human CCD-19Lu cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30108778]
CCRF-CEM	IC₅₀	0.036 μM Compound: mitoxantrone	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
CH1	IC₅₀	0.00265 μM Compound: Mitoxantrone	Concentration required to inhibit CH1-cell growth by 50% Concentration required to inhibit CH1-cell growth by 50%	[PMID: 9703471]
CH1	IC₅₀	0.00265 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit CH1 cell growth by 50% Cytotoxic potency required to inhibit CH1 cell growth by 50%	[PMID: 9371240]
CHO	IC₅₀	22.5 μM Compound: mitoxantrone	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
Daudi	IC₅₀	0.005 μM Compound: Mit	Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay	[PMID: 25998504]
G-361	IC₅₀	0.00065 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit G-361 cell growth by 50% Cytotoxic potency required to inhibit G-361 cell growth by 50%	[PMID: 9371240]
H22	IC₅₀	187 nM Compound: Mitoxantrone	Dark toxicity against mouse H22 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay Dark toxicity against mouse H22 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	[PMID: 30925340]
HaCaT	IC₅₀	3.9 μM Compound: Mitoxantrone	Cytotoxicity against human HaCaT cells by Cell titre-blue assay Cytotoxicity against human HaCaT cells by Cell titre-blue assay	[PMID: 26684177]
HCC78	IC₅₀	13.83 nM Compound: Mitoxantrone	Cytotoxicity in human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 30108778]
HCT-116	IC₅₀	0.022 μM Compound: Mx	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
HCT-116	IC₅₀	0.025 μM Compound: Mit	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25998504]
HCT-116	IC₅₀	1.61 μM Compound: Mitoxantrone	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29407981]
HCT-116	IC₅₀	110 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human HCT116 cancer cell line was determined after 1 hr Cytotoxicity against human HCT116 cancer cell line was determined after 1 hr	[PMID: 15456268]
HCT-116	IC₅₀	3.96 μM Compound: Mitoxantrone	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 20951582]
HCT-116	IC₅₀	5.8 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr	[PMID: 15456268]
HCT-116	IC₅₀	7.2 μM Compound: Mitoxantrone	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21507644]
HCT-116	IC₅₀	7.2 μM Compound: Mitoxantrone	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 21458279]
HEK293	IC₅₀	0.4 μM Compound: mitoxantrone	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis	[PMID: 23241029]
HEK293	IC₅₀	0.53 μM Compound: mitoxantrone	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	0.53 μM Compound: mitoxantrone	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	0.83 μM Compound: mitoxantrone	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	10 nM Compound: Mitoxantrone	Cytotoxicity against HEK293 cells after 72 hrs by MTT assay Cytotoxicity against HEK293 cells after 72 hrs by MTT assay	[PMID: 24611893]
HEK293	IC₅₀	11.7 nM Compound: Mitoxantrone	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	[PMID: 31465686]
HEK293	IC₅₀	26.6 nM Compound: Mitoxantrone	Cytotoxicity against HEK293 cells overexpressing ABCG2 after 72 hrs by MTT assay Cytotoxicity against HEK293 cells overexpressing ABCG2 after 72 hrs by MTT assay	[PMID: 24611893]
HEK293	IC₅₀	43.9 μM Compound: mitoxantrone	Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	60.5 μM Compound: mitoxantrone	Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	73.3 μM Compound: mitoxantrone	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK-293T	IC₅₀	< 0.1 μM Compound: mitoxantrone	Cytotoxicity against human 293T cells expressing telomerase after 96 hrs by MTT assay Cytotoxicity against human 293T cells expressing telomerase after 96 hrs by MTT assay	[PMID: 18754611]
HeLa	IC₅₀	< 0.1 μM Compound: mitoxantrone	Cytotoxicity against human HeLa cells expressing telomerase after 96 hrs by MTT assay Cytotoxicity against human HeLa cells expressing telomerase after 96 hrs by MTT assay	[PMID: 18754611]
HeLa	IC₅₀	0.044 μM Compound: Mit	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25998504]
HeLa	EC₅₀	0.55 μg/mL Compound: 4	Effective concentration required to inhibit by 50% the growth of HeLa S3 cells Effective concentration required to inhibit by 50% the growth of HeLa S3 cells	[PMID: 3172129]
HeLa	IC₅₀	2.35 μM Compound: Mitoxantrone	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29407981]
HepG2	IC₅₀	11.05 μM Compound: Mitoxantrone	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24794747]
HepG2	IC₅₀	15.33 μM Compound: MTZ	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33191085]
HepG2	IC₅₀	18.6 μM Compound: Mitoxantrone	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29407981]
HL-60	IC₅₀	0.0025 μM Compound: Mitoxantrone	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	[PMID: 22944121]
HL-60	GI₅₀	0.01 μM Compound: mitoxantrone	Growth inhibition of human HL60 cells by Almar blue assay Growth inhibition of human HL60 cells by Almar blue assay	[PMID: 17418582]
HL-60	IC₅₀	0.016 μM Compound: mitoxantrone	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
HL-60	IC₅₀	0.024 nM Compound: Mitoxantrone	Antiproliferative activity against human HL60 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HL60 cells after 72 hrs by CCK8 assay	[PMID: 30485090]
HL-60	IC₅₀	0.063 μM Compound: MX	Cytotoxicity against human HL60 cells after 72 hrs Cytotoxicity against human HL60 cells after 72 hrs	[PMID: 20961767]
HL-60	IC₅₀	0.063 μM Compound: MX, mitoxantrone	Cytotoxicity against human mitoxantrone-sensitive HL60 cells after 72 hrs Cytotoxicity against human mitoxantrone-sensitive HL60 cells after 72 hrs	[PMID: 18507368]
HL-60	GI₅₀	0.192 μg/mL Compound: mitoxantrone	Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HL-60	IC₅₀	0.29 μg/mL Compound: mitoxantrone	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 10843567]
HL-60	GI₅₀	0.33 nM Compound: MX, mitoxantrone	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 17962028]
HL-60	IC₅₀	1.51 μM Compound: MX	Cytotoxicity against human HL60/MX2 cells after 72 hrs Cytotoxicity against human HL60/MX2 cells after 72 hrs	[PMID: 20961767]
HL-60	IC₅₀	4 nM Compound: MITO	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	[PMID: 29945793]
HL-60	IC₅₀	4 nM Compound: MITO	Cytotoxicity against human HL60 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HL60 cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
HL-60	IC₅₀	6.3 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19615900]
HL-60	IC₅₀	6.8 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19926279]
HL-60	IC₅₀	7.5 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 20951582]
HL-60	GI₅₀	7.8 μM Compound: Mitoxantrone	Growth inhibition of human HL60 cells by MTT assay Growth inhibition of human HL60 cells by MTT assay	[PMID: 20153184]
HL-60	IC₅₀	7.9 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 21458279]
HL-60	IC₅₀	8.1 μM Compound: MX	Cytotoxicity against human HL60 cells after 72 hrs Cytotoxicity against human HL60 cells after 72 hrs	[PMID: 21354791]
HL-60	IC₅₀	8.2 μM Compound: Mitoxantrone	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 21507644]
HL60/MX2	IC₅₀	0.561 μM Compound: Mitoxantrone	Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay	[PMID: 22944121]
HL60/MX2	IC₅₀	1.51 μM Compound: MX, mitoxantrone	Cytotoxicity against mitoxantrone-resistant human HL60/MX2 cells after 72 hrs Cytotoxicity against mitoxantrone-resistant human HL60/MX2 cells after 72 hrs	[PMID: 18507368]
HL60/MX2	IC₅₀	148 nM Compound: MITO	Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay	[PMID: 29945793]
HL60/MX2	IC₅₀	148 nM Compound: MITO	Cytotoxicity against human HL60/MX2 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HL60/MX2 cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
HL60/MX2	GI₅₀	26 nM Compound: MX, mitoxantrone	Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay	[PMID: 17962028]
HL60/MX2	GI₅₀	4.42 μg/mL Compound: mitoxantrone	Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HT-29	IC₅₀	0.01 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit HT-29 cell growth by 50% after cell drug contact for 144 hrs Cytotoxic potency required to inhibit HT-29 cell growth by 50% after cell drug contact for 144 hrs	[PMID: 9371240]
HT-29	IC₅₀	0.01 μM Compound: MX	Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line	[PMID: 11563932]
HT-29	IC₅₀	0.025 μM Compound: Mx	Antiproliferative activity against HT29 cells by MTT assay after 72 hrs Antiproliferative activity against HT29 cells by MTT assay after 72 hrs	[PMID: 16824751]
HT-29	IC₅₀	21.65 μM Compound: Mitoxantrone	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 29407981]
HT-29	IC₅₀	8.7 μM Compound: Mitoxantrone	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 19615900]
HT-29	GI₅₀	8.9 μM Compound: Mitoxantrone	Growth inhibition of human HT-29 cells by MTT assay Growth inhibition of human HT-29 cells by MTT assay	[PMID: 20153184]
Ishikawa	IC₅₀	0.01 μM Compound: Mit	Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay	[PMID: 25998504]
K562	IC₅₀	0.0026 μM Compound: mitoxantrone	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
K562	IC₅₀	0.0334 μg/mL Compound: mitoxantrone	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 10843567]
K562	IC₅₀	0.42 μM Compound: Mitoxantrone	Growth inhibition of human K562 cells after 72 hrs by MTS method Growth inhibition of human K562 cells after 72 hrs by MTS method	[PMID: 18258442]
K562	IC₅₀	0.51 μM Compound: mitoxantrone	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
K562	IC₅₀	2 μg/mL Compound: mitoxanthrone	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 12027731]
K562	IC₅₀	2.35 μM Compound: MTZ	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33191085]
K562	IC₅₀	4.55 μM Compound: Mitoxantrone	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 29407981]
KB	EC₅₀	0.355 μg/mL Compound: Mitoxantrone	Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay	[PMID: 21458262]
KB	EC₅₀	0.36 μM Compound: mitoxantrone	Antiproliferative activity against human KB/HeLa cells after 48 hrs Antiproliferative activity against human KB/HeLa cells after 48 hrs	[PMID: 23395656]
KB	EC₅₀	0.42 μM Compound: Mitoxantrone	Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay	[PMID: 23988351]
L1210	EC₅₀	> 5 μg/mL Compound: 4	Effective concentration required to inhibit by 50% the growth of L1210 cells Effective concentration required to inhibit by 50% the growth of L1210 cells	[PMID: 3172129]
L1210	IC₅₀	0.00004 μM Compound: mitoxantrone	Cytotoxic potency required to inhibit L1210 cell growth by 50% after cell drug contact for 48 hrs Cytotoxic potency required to inhibit L1210 cell growth by 50% after cell drug contact for 48 hrs	[PMID: 9371240]
L1210	IC₅₀	10 nM Compound: mitoxantrone	Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	15 μM Compound: Mitoxantrone	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28222315]
L1210	IC₅₀	39 nM Compound: Mitoxantrone	Antitumor activity against murine L1210 resistant cell line by using MTT assay Antitumor activity against murine L1210 resistant cell line by using MTT assay	[PMID: 7699715]
L1210	IC₅₀	39 nM Compound: mitoxantrone	Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	5 nM Compound: Mitoxantrone	Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay	[PMID: 7699715]
LoVo	IC₅₀	12 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human LoVo cancer cell line was determined after 1 hr Cytotoxicity against human LoVo cancer cell line was determined after 1 hr	[PMID: 15456268]
LoVo	IC₅₀	3.3 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human LoVo cancer cell line was determined after 144 hr Cytotoxicity against human LoVo cancer cell line was determined after 144 hr	[PMID: 15456268]
MCF7	GI₅₀	3.93 μM Compound: MX, mitoxantrone	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 17962028]
MCF7	IC₅₀	380.2 nM Compound: Mitoxantrone	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	[PMID: 30925340]
MCF7	IC₅₀	41 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	7.1 μM Compound: Mitoxantrone	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21458279]
MCF7	IC₅₀	7.1 μM Compound: Mitoxantrone	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19615900]
MCF7	IC₅₀	72 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	9 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MDA-MB-231	IC₅₀	0.96 μM Compound: mitoxantrone	Antiproliferative activity against human MDA-MB-231 cells by WST-1 method after 72 hrs Antiproliferative activity against human MDA-MB-231 cells by WST-1 method after 72 hrs	[PMID: 17335189]
MDA-MB-435	IC₅₀	0.35 nM Compound: Mitoxantrone	Antiproliferative activity against MDA435/LCC6 cells by ELISA Antiproliferative activity against MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	1442 nM Compound: Mitoxantrone	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	646 nM Compound: Mitoxantrone	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
MDCK-II	IC₅₀	0.19 μM Compound: mitoxantrone	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	[PMID: 23241029]
MES-SA	IC₅₀	0.003 μM Compound: Mx	Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs	[PMID: 16824751]
MES-SA	IC₅₀	0.006 μM Compound: Mit	Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay	[PMID: 25998504]
MES-SA	IC₅₀	0.012 μM Compound: Mx	Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
MES-SA/Dx5	IC₅₀	0.028 μM Compound: Mx	Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs	[PMID: 16824751]
MES-SA/Dx5	IC₅₀	0.073 μM Compound: Mit	Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay	[PMID: 25998504]
MES-SA/Dx5	IC₅₀	0.08 μM Compound: Mx	Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
MKN-28	IC₅₀	0.02 μg/mL Compound: mitoxantrone	Cytotoxicity against human MKN28 cells after 48 hrs by MTT assay Cytotoxicity against human MKN28 cells after 48 hrs by MTT assay	[PMID: 10843567]
MKN-45	IC₅₀	12 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human MKN45 cancer cell line was determined after 144 hr Cytotoxicity against human MKN45 cancer cell line was determined after 144 hr	[PMID: 15456268]
NCI-H460	EC₅₀	0.03 μM Compound: Mitoxantrone	Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay	[PMID: 23988351]
NCI-H460	EC₅₀	0.12 μM Compound: mitoxantrone	Antiproliferative activity against human NCI-H460 cells after 48 hrs Antiproliferative activity against human NCI-H460 cells after 48 hrs	[PMID: 23395656]
NCI-H460	EC₅₀	0.1224 μg/mL Compound: Mitoxantrone	Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay	[PMID: 21458262]
NCI-H460	IC₅₀	0.36 μM Compound: MX	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability incubated for 2 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability incubated for 2 hrs by MTT assay	[PMID: 31302589]
NCI-H460	GI₅₀	1.29 μM Compound: MX, mitoxantrone	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 17962028]
NIH3T3	IC₅₀	42 μM Compound: Mitoxantrone	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28222315]
OVCAR-3	IC₅₀	5.8 nM Compound: Mitoxantrone	Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay	[PMID: 7699715]
OVCAR-3	IC₅₀	6 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.	[PMID: 10956214]
P388	IC₅₀	4.3 nM Compound: Mitoxantrone	Antiproliferative activity against P388 cells by ELISA Antiproliferative activity against P388 cells by ELISA	[PMID: 17154505]
P388/ADR	IC₅₀	194 nM Compound: Mitoxantrone	Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
P388/ADR	IC₅₀	395 nM Compound: Mitoxantrone	Antiproliferative activity against adriamycin resistant P388 cells by ELISA Antiproliferative activity against adriamycin resistant P388 cells by ELISA	[PMID: 17154505]
PC-3	IC₅₀	0.29 μM Compound: Mitoxantrone	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 22100139]
PC-3	GI₅₀	0.78 μM Compound: MX, mitoxantrone	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 17962028]
PC-3	IC₅₀	7 nM Compound: MX (Mitoxantrone)	Cytotoxicity against human PC3 cancer cell line was determined after 144 hr Cytotoxicity against human PC3 cancer cell line was determined after 144 hr	[PMID: 15456268]
SF-268	EC₅₀	0.315 μg/mL Compound: Mitoxantrone	Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay	[PMID: 21458262]
SF-268	EC₅₀	0.32 μM Compound: mitoxantrone	Antiproliferative activity against human SF268 cells after 48 hrs Antiproliferative activity against human SF268 cells after 48 hrs	[PMID: 23395656]
SF-268	GI₅₀	0.97 μM Compound: MX, mitoxantrone	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 17962028]
SGC-7901	IC₅₀	0.293 nM Compound: Mitoxantrone	Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay	[PMID: 30485090]
SK-OV-3	IC₅₀	0.0053 μM Compound: Mitoxantrone	Concentration required to inhibit SKOV-3-cell growth by 50% Concentration required to inhibit SKOV-3-cell growth by 50%	[PMID: 9703471]
SK-OV-3	EC₅₀	0.12 μM Compound: mitoxantrone	Antiproliferative activity against human SKOV3 cells after 48 hrs Antiproliferative activity against human SKOV3 cells after 48 hrs	[PMID: 23395656]
SK-OV-3	EC₅₀	0.1207 μg/mL Compound: Mitoxantrone	Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay	[PMID: 21458262]
SK-OV-3	GI₅₀	11 μM Compound: Mitoxantrone	Growth inhibition of human SKOV3 cells by MTT assay Growth inhibition of human SKOV3 cells by MTT assay	[PMID: 20153184]
SK-OV-3	IC₅₀	9.8 μM Compound: Mitoxantrone	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 19615900]
U-937	IC₅₀	6.2 μM Compound: Mitoxantrone	Cytotoxicity against human U937 cells by MTT assay Cytotoxicity against human U937 cells by MTT assay	[PMID: 19615900]
UACC-375	IC₅₀	48 nM Compound: Mitoxantrone	Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay	[PMID: 7699715]
UACC-375	IC₅₀	48 nM Compound: mitoxantrone	Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.	[PMID: 10956214]
WiDr	IC₅₀	488 nM Compound: mitoxantrone	Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]
WiDr	IC₅₀	8 nM Compound: mitoxantrone	Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]

In Vitro

Mitoxantrone inhibits PKC in a competitive manner with respect to histone H1, and its K_i value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP^[1].
Mitoxantrone (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone is due to induction of apoptosis^[2].
Mitoxantrone shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC₅₀ values of 18 and 196 nM, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mitoxantrone (IP, 0-3.2 mg/kg/day) produces a statistically significant number of 60-day survivors at 1.6 mg/kg in mice with IP implanted L1210 leukemia^[4].
Mitoxantrone (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

444.48

Formula

C₂₂H₂₈N₄O₆

CAS No.

65271-80-9

Appearance

Solid

Color

Brown to black

SMILES

O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 35 mg/mL (78.74 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2498 mL	11.2491 mL	22.4982 mL
5 mM	0.4500 mL	2.2498 mL	4.4996 mL
10 mM	0.2250 mL	1.1249 mL	2.2498 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.70%

Select Batch:

Data Sheet (281 KB) SDS (393 KB)

COA (251 KB) HNMR (271 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7. [Content Brief]

[2]. Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. [Content Brief]

[3]. Vibet S, et al. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007 May;35(5):822-8. [Content Brief]

[4]. Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62. [Content Brief]

[5]. Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308. [Content Brief]

Cell Assay ^[3]	The human breast carcinoma cell lines MDA-MB-231 and MCF-7 are seeded in standard 96-well plates. One day after seeding, the culture medium is changed and replaced by medium containing different concentration of Mitoxantrone (10^-5 to 5 μM) with or without DHA (30 μM) during 7 days. Viability of cells are measured as a whole by the tetrazolium salt assay^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[4]	Mice: Mitoxantrone is tested for antitumor activity against experimental tumors in mice and the results are compared with those of seven antitumor antibiotics. The drugs are given IP or IV, in general on days 1, 5, and 9 following tumor inoculation. Mitoxantrone is given IP at the optimal dose (1.6 mg/kg/day; as a free base)^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7. [Content Brief] [2]. Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. [Content Brief] [3]. Vibet S, et al. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007 May;35(5):822-8. [Content Brief] [4]. Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62. [Content Brief] [5]. Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2498 mL	11.2491 mL	22.4982 mL	56.2455 mL
	5 mM	0.4500 mL	2.2498 mL	4.4996 mL	11.2491 mL
	10 mM	0.2250 mL	1.1249 mL	2.2498 mL	5.6245 mL
	15 mM	0.1500 mL	0.7499 mL	1.4999 mL	3.7497 mL
	20 mM	0.1125 mL	0.5625 mL	1.1249 mL	2.8123 mL
	25 mM	0.0900 mL	0.4500 mL	0.8999 mL	2.2498 mL
	30 mM	0.0750 mL	0.3750 mL	0.7499 mL	1.8748 mL
	40 mM	0.0562 mL	0.2812 mL	0.5625 mL	1.4061 mL
	50 mM	0.0450 mL	0.2250 mL	0.4500 mL	1.1249 mL
	60 mM	0.0375 mL	0.1875 mL	0.3750 mL	0.9374 mL

Mitoxantrone Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Mitoxantrone (Synonyms: Mitozantrone; NSC 301739)

Customer Review

Other Forms of Mitoxantrone:

29 Publications Citing Use of MCE Mitoxantrone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All PKC Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Mitoxantrone Related Classifications

Keywords:

Your Recently Viewed Products:

Mitoxantrone (Synonyms: Mitozantrone; NSC 301739)

Customer Review

Other Forms of Mitoxantrone:

Mitoxantrone Related Antibodies

29 Publications Citing Use of MCE Mitoxantrone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All PKC Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Mitoxantrone Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Mitoxantrone Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report